Abstract:Kazuhiro Furumachi, 1 Tatsuki Kagatsume, 2 Akari Higuchi, 2 Mariko Kozaru, 2 Etsuko Kumagai, 1 Keiko Hosohata 2 1 Department of Nephrology, Kenwakai Hospital, Nagano, Japan; 2 Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan Correspondence: Keiko Hosohata, Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan, Tel +81-72-690-1271, Fax +81-72-690-1023, Email Purpose: The aim of the study was to determine the association between coronavirus disease 2019 (COVID-19) infection and diabetes management indices in patients with type 2 diabetes mellitus. Patients and Methods: A single-center, retrospective, observational study of patients with type 2 diabetes mellitus at Kenwakai Hospital (Nagano, Japan) was conducted. Data of 95 patients (mean age, 72 ± 12 years; men, 67.4%) who visited between March 1, 2019 and February 28, 2022 were obtained from the hospital's electronic information system. COVID-19 was diagnosed by a chemiluminescent enzyme immunoassay (CLEIA). Results: There was no association between COVID-19 infection and age, sex, hemodialysis treatment status, or the Charlson Comorbidity Index. After adjustment for possible confounding factors, the incidence of COVID-19 infection was significantly correlated with HbA1c ≥ 7.0% (odds ratio [OR], 5.51; 95% confidence interval [CI], 1.30– 23.26). Conclusion: The results suggest an association between high HbA1c levels and COVID-19 infection in patients with type 2 diabetes mellitus. Appropriate management of diabetes mellitus, focusing on HbA1c levels, may help prevent COVID-19 infection and severe disease after infection. Keywords: Type 2 diabetes mellitus, COVID-19, risk factors, HbA1c, Japanese Diabetes mellitus increases the risk of infectious diseases, regardless of whether it is type 1 or 2. 1 In particular, poor glycemic control can lead to increased susceptibility to infection due to decreased phagocytic and bactericidal functions of polymorphonuclear neutrophils and decreased complement binding to antigen-antibody complexes, 2–5 increased susceptibility to severe infections, 6 and increased risks of hospitalization and death. 7–9 Epidemics of SARS (2003) and H1N1 influenza (2009) have shown that a history of diabetes mellitus is an independent factor that increases the risks of hospitalization and severe illness, 10–12 and vaccination is recommended to prevent severe illness caused by viral infections. 13 Similarly, for the COVID-19 pandemic since 2020, a history of diabetes mellitus was found to increase the risk of severe disease, 14 whereas no consistent trend has emerged regarding the impact of diabetes mellitus on the risk of COVID-19 infection itself. Reports from Europe, the United States, and China have shown no clear difference in the prevalence of diabetes mellitus in COVID-19-infected patients compared with control populations. 15,16 In Japan, the prevalence of diabetes mellitus in hospitalized patients with COVID-19 infection was similar to the prevalence in the same age group in the general population; 17 therefore, we cannot definitively say that diabetes mellitus increases the risk of COVID-19 infection. In addition, which baseline information, including type 2 diabetes indices, is the most associated with COVID-19 infection has yet to be clarified. The aim of this study was to retrospectively examine the association between type 2 diabetes mellitus and the risk of COVID-19 infection using real-world clinical data. This was a retrospective, observational, cohort study, which was approved by the Ethics Committee of Kenwakai Hospital (No. 2023004) and Osaka Medical and Pharmaceutical University (No. 2323–061) and was conducted in accordance with the Declaration of Helsinki. The Ethics Committee waived the need for informed consent from patients because of the retrospective and anonymous nature of the study. Data of eligible patients (≥20 years) with type 2 diabetes mellitus who visited Kenwakai Hospital (Nagano, Japan) between March 1, 2019 and February 28, 2022 were collected. The data of patients without information on HbA1c (n = 1), body mass index (BMI) (n = 6), or smoking status (n = 21), as well as of patients who did not receive continuous treatment with antidiabetic agents (n = 53), were excluded. Finally, the remaining 95 patients were included in the present analyses (Figure 1). Figure 1 Flow chart of the study cohort. In daily practice, COVID-19 was diagnosed by a chemiluminescence enzyme immunoassay -Abstract Truncated-

Diabetes and the risk of coronary heart disease in the general Japanese population: the Japan Public Health Center-based prospective (JPHC) study

Association Between Parental History of Diabetes and the Incidence of Type 2 Diabetes Mellitus Differs According to the Sex of the Parent and Offspring's Body Weight: A Finding from a Japanese Worksite-Based Cohort Study.

Similarities and Differences Between Coronary Heart Disease and Stroke in the Associations with Cardiovascular Risk Factors: the Japan Collaborative Cohort Study.

Higher Cardiorespiratory Fitness During A Given Period and Lower Incidence of Type 2 Diabetes

Diabetes mellitus and risk of stroke and its subtypes among Japanese: the Japan public health center study

Impact of hypertension stratified by diabetes on the lifetime risk of cardiovascular disease mortality in Japan: a pooled analysis of data from the Evidence for Cardiovascular Prevention from Observational Cohorts in Japan study

Hemoglobin a1c levels and the risk of cardiovascular disease in people without known diabetes: a population-based cohort study in Japan

1372-P: Association between Fat Intake as the Percent of Total Energy and Incidence of Cardiovascular Disease in Persons with Type 2 Diabetes—Japan Diabetes Complication and Its Prevention Prospective Study (JDCP Study)

A large-scale observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 1 diabetes—JDCP study 2

Importance of Achieving a “fit” Cardiorespiratory Fitness Level for Several Years on the Incidence of Type 2 Diabetes Mellitus: A Japanese Cohort Study

A large-scale, observational study to investigate the current status of diabetes complication and their prevention in Japan: incidence/risk factors for malignancies during follow-up-JDCP study 11 (English version)

A large-scale, observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 2 diabetes—JDCP study 1

The combined impact of blood pressure category and glucose abnormality on the incidence of cardiovascular diseases in a Japanese urban cohort: the Suita Study

Diabetes and Mortality from Respiratory Diseases: the Japan Collaborative Cohort Study

Diabetes and cancer risk: A Mendelian randomization study

Impact of hypertension and diabetes on the onset of chronic kidney disease in a general Japanese population

Associations of impaired glucose metabolism and dyslipidemia with cardiovascular diseases: what have we learned from Japanese cohort studies for individualized prevention and …

Association Between COVID-19 and Diabetes Management Indices in Japanese Type 2 Diabetes Mellitus Patients: A Single-Center, Retrospective Study

Non-linear Relationship Between High-Density Lipoprotein Cholesterol and Incident Diabetes Mellitus: a Secondary Retrospective Analysis Based on a Japanese Cohort Study

Dietary potassium intake and its interaction with sodium intake on risk of developing cardiovascular disease in persons with type 2 diabetes: The Japan Diabetes Complication and its Prevention Prospective study (JDCP study 12)

Causes of death in Japanese patients with diabetes based on the results of a survey of 68,555 cases during 2011–2020: Committee report on causes of death in diabetes mellitus, Japan Diabetes Society (English version)